News
The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. Scientists say this ...
EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.
1d
DPA International on MSNEMA recommends approval of additional Alzheimer's treatment
The European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.
The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the ...
The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...
Paris: Sanofi has announced that the European Commission has approved Sarclisa in combination with bortezomib, lenalidomide, ...
Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...
The drug is administered subcutaneously twice a year, making it easier for high-risk patients to comply with prophylaxis.
Sarepta Therapeutics failed to win the European drug regulator's backing for its muscle disorder gene therapy on Friday, as ...
European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.
Despite a new setback for Elevidys in Europe, Roche—which markets Sarepta’s gene therapy outside the U.S.—remains committed ...
Eli Lilly and Co. won the backing of European Union regulators for its Alzheimer’s disease drug Kisunla in a specific group ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results